Ibruxen 140 mg, containing the active ingredient Ibrutinib, is a targeted cancer therapy indicated for the treatment of several B-cell malignancies. It is primarily used in patients who have limited options due to prior therapy. Its approved indications include:

• Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.

• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Including patients with 17p deletion, offering effective disease control in genetically high-risk patients.

• Waldenström Macroglobulinemia (WM): For patients with symptomatic disease requiring treatment.

• Marginal Zone Lymphoma (MZL): For patients requiring systemic therapy who have received at least one prior anti-CD20-based therapy.

By specifically targeting abnormal B-cell signaling pathways, Ibruxen 140 mg helps reduce malignant B-cell proliferation, improving disease management and patient outcomes.

Description

Ibruxen 140 mg is an oral small-molecule inhibitor of Bruton’s Tyrosine Kinase (BTK). BTK is a critical enzyme in the B-cell receptor (BCR) signaling pathway, which regulates B-cell survival, proliferation, adhesion, and migration. By irreversibly binding to BTK at the active site, Ibruxen inhibits its enzymatic activity, blocking downstream signaling and preventing cancerous B-cells from multiplying or spreading.

Pharmacology

Ibruxen selectively inhibits BTK, a key mediator in the B-cell receptor and cytokine receptor pathways. Preclinical studies show that BTK inhibition by Ibruxen:

• Suppresses malignant B-cell proliferation and survival.

• Reduces B-cell migration and adhesion to substrates.

• Disrupts signaling pathways critical for leukemia and lymphoma progression, including chemotaxis and trafficking of malignant B-cells.

Its targeted mechanism allows for selective action against cancer cells while minimizing effects on normal tissues.

Dosage & Administration

• MCL and MZL: 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

• CLL/SLL and WM: 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

• CLL/SLL in combination with bendamustine and rituximab: 420 mg orally once daily throughout combination therapy cycles.

Administration: Take capsules orally at the same time each day. Swallow whole with water; do not open, break, or chew.

Drug Interactions

• CYP3A Inhibitors: Strong or moderate inhibitors can increase Ibruxen levels; dose adjustment may be required.

• CYP3A Inducers: Strong inducers can reduce drug efficacy and should be avoided.

Contraindications

• Known hypersensitivity to Ibrutinib or any of the excipients.

Side Effects

Common adverse effects include diarrhea, infections, cytopenias, atrial fibrillation, hypertension, hemorrhage, visual disturbances, tumor lysis syndrome, and second primary malignancies. Severe reactions may require dose adjustment or temporary discontinuation. Patients should be closely monitored for infections, bleeding, and cardiac complications.

Pregnancy & Lactation

• Pregnancy: Ibruxen may cause fetal harm. Animal studies show embryofetal toxicity at doses exceeding clinical levels. Patients should be informed of potential risks and advised on effective contraception.

• Lactation: Safety is unknown; breastfeeding is not recommended during treatment.

Overdose

Limited clinical experience exists. One healthy volunteer experienced reversible Grade 4 liver enzyme elevation after 1680 mg. Supportive care and close monitoring are recommended in cases of overdose.

Special Populations

• Pediatric Use: Safety and efficacy not established.

• Geriatric Use: No overall differences in effectiveness, but older patients may have a higher risk of anemia or pneumonia.

• Hepatic Impairment: Ibruxen is metabolized in the liver; moderate to severe hepatic impairment is not recommended due to increased drug exposure. Dose modification may be necessary in mild impairment.

Therapeutic Class

Targeted Cancer Therapy

Storage Conditions

Store in a dry place below 30°C, protected from light. Keep out of reach of children.